Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC

NCT06088771 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

BIOLOGICAL: Dupilumab
BIOLOGICAL: Cemiplimab

Sponsor

Icahn School of Medicine at Mount Sinai